rs114809809 (EPHB2): Macular Degeneration and VLDL

Key takeaways

• Depletion of very small VLDL particles in blood is likely a causal driver of age-related macular degeneration, based on a 72,376-person UK Biobank study.
• 84 blood metabolic markers were significantly associated with AMD; lipoprotein subclasses made up 39% of these findings.
• Mendelian randomization supported a causal role for very small VLDL in AMD, not just an association.
• Age is the biggest predictor of AMD risk; lipid metabolites add a smaller but measurable contribution.
• Evidence is from a single study and has not yet been independently replicated.

What the research says A three-tiered analysis of 325 blood metabolites in 72,376 UK Biobank donors (1,353 AMD cases and 71,023 controls) identified 84 metabolic markers significantly associated with age-related macular degeneration (AMD) after false discovery rate correction. Genome-wide association studies (GWAS) of these metabolites were conducted in 98,316 European-ancestry participants to identify metabolite-linked genetic loci. Two-sample Mendelian randomization - a method that uses genetic variants as proxies to test causal effects rather than mere statistical associations - identified 19 metabolites with a putatively causal role in AMD, with six very small very low-density lipoprotein (VLDL) subclasses and the phospholipids-to-total-lipid ratio in medium VLDL singled out as the strongest causal candidates.

Reported associations

• Age-related macular degeneration (AMD): Lipoprotein subclasses comprised 39% of 84 significantly AMD-associated metabolic markers in a UK Biobank cohort of 72,376 donors; six very small VLDL-related lipoproteins were identified as likely causal contributors through Mendelian randomization.
• VLDL lipoprotein subclass levels: Depletion of circulating very small VLDL subclasses is postulated as likely causal for AMD, based on GWAS in 98,316 European-ancestry participants followed by Mendelian randomization analysis.
• AMD risk prediction: A machine learning classifier combining metabolite profiles with age and sex found age to be the primary predictive factor, with lipoprotein subclasses contributing a smaller but measurable incremental component to AMD risk.

Evidence quality This study, published in Ophthalmology Science (2024), analyzed 325 blood metabolites in 72,376 UK Biobank donors (1,353 AMD cases, 71,023 controls) and conducted GWAS in 98,316 European-ancestry participants. Statistical significance for metabolite-AMD associations used a false discovery rate-adjusted threshold (adjusted p < 0.05). Two-sample Mendelian randomization was used to move from observational association to putative causation for a subset of 19 metabolites. The study population was restricted to European ancestry, limiting generalizability to other populations. The authors describe the causal role of very small VLDL subclasses as "likely" rather than definitively established, and the provided study text does not report individual variant-level effect sizes such as odds ratios or beta coefficients for specific metabolite-AMD associations. No independent replication study is cited within the provided text, and the evidence should be considered preliminary.

Lifestyle considerations No lifestyle considerations on file for this variant.